When mice had developed antitumor immunity against F10 with a foreign antigen, OVA, the authors found that VEGF-C conferred immune tolerance to F10 OVA immunity by deleting OVA-specific CD8 + T cells in the tumor site. Here, CD8A is linked to neoplasm.